
IPO
CGEM.NASDAQ
Minulé
Cullinan Management
Developer of an externally sourced cancer therapeutics used to end a drug program quickly
Stránky společnostiTicker
CGEM.NASDAQ
Trh
us
Rok založení
2017
Uzávěrka
2/7/2021
Datum IPO
1/7/2021
Cena umístění
$21
Ziskovost
72.33%
O společnosti
Total Funding
$389.7M
Cullinan Oncology is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enabling researchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model.
Number of employees
11-50
Headquarters
Cambridge, Massachusetts, United States